Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Maximilian J MairAyseguel Ilhan-MutluSahra PajendaBarbara KieselAdelheid WöhrerGeorg WidhalmKarin DieckmannChristine MarosiLudwig WagnerMatthias PreusserAnna Sophie BerghoffPublished in: Cancer immunology, immunotherapy : CII (2021)
Changes in systemic inflammation markers including sPD-L1 are observable in patients with recurrent glioma under bevacizumab-based treatment and differ between WHO grade II-III glioma and GBM.
Keyphrases